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or COPD in picking up newly diagnosed CHF is approximately 20%. This group of 
patients presents a substantial therapeutic opportunity for the initiation and chronic 
administration of ACEI and BB therapy as well as other CHF management strategies. 
1013-76 Influence of Creatinine on Plasma Concentrations and 
the Prognostic Value of N-Terminal Pro-BNP in Severe 
Chronic Heart Failure: Data From a Substudy of the 
COPERNICUS Trial 
Franz S. Hartmann, lldiko Amann-Zalan, Silke Hoersch, Hugo A. Katus, Medicine Klinik 
II, UKL, Luebeck, Germany, lnnere Medizin Ill, Medicine University Heidelberg, 
Heidelberg, Germany 
Background: The impact of creatinine levels on plasma concentrations as well as the 
prognostic value of N-terminal proENP (pmBNP) was evaluated in patients with symp- 
toms of congestive heart failure (CHF) at rest or on minimal exertion. 
Methods: Plasma concentrations of proBNP, were measured using a newly developed 
sandwich ELISA in a subgroup of 1048 patrents of the European part of the COPERNI- 
CUS study. 
Results: ProBNP baseline values, mean*SD. were 74lilO16 pmol/L in patients with ele- 
vated (a=125 U/L) creatinine, compared to 403~461 pmollL in patients with normal 
(cl25UiL) creatinine (p=O.OOOl, Wilcoxon P-sample test). A significant positive correla- 
tion (r= 0.35, p=O.OOOl, Pearson Correlation Coefficient) was detected between proBNP 
and creatinine. By multivariate Cox regression, NT-proBNP but not creatinine was a pow- 
erful independent indicator of subsequent cardiac events. A statistical significant creati- 
nine-proBNP interaction could be detected (p=O.O2 for the primary endpoint), indicating 
that the prognostic value of proBNP for survival is not constant Over the range of creati- 
nine. Risk ratios for proBNP levels below vs. above median are indicated in the table 
according to quartiles of baseline creatinine. 
Conclusions: In patients wtth advanced CHF treated wrthin the COPERNICUS study, 
proBNP plasma concentrations are related to creatinine both at baseline and during 
treatment. In addihon, baseline creatinine levels seam to influence the prognostic value 
of proBNP concentrations. 
Risk Ratios for all-cause mortalrty for proBNP (below median : above median) according to 
creatimne 
Creatinine quartile Risk ratio 95% C.I. P-value (log rank test) 
Quartile 1 (cl11 U/L) 2.51 1.01-6.21 0.0397 
Quartile 2+3 (1 II-146 U/L) 3.29 1.57-6.69 0.0006 
Quartile 4 (>148 U/L) 3.64 1.27-I 0.44 0.0103 
1013-77 Extent and Not Nature of Dysfunctional Myocardium Is 
the Main Determinant of B-Type Natriuretic Peptide in 
Patients With lschemic Left Ventricular Dysfunction 
Charles A. Nelson, Jane McCrohon, Stephen Rose, Thomas H. Marwick, University of 
Queensland, Brisbane, Australia 
Background: B-type Natrfuretic Peptide (BNP) reflects LV filling pressures, but the 
determinants of BNP release in ischemic LV dysfunction (eg. roles of global LV size and 
function, regional wall stress and myocardial viability) are unclear. 
Methods: BNP (Biosite, San Diego) was measured in 32 pts (age 45 -75) with LV dys- 
function after infarction. MRI was used to measure LVEDV, LVESV and LVEF, and iden- 
tify dysfunctional myocardium. The LV was divided into 64 subsegments after dividing 
the 16 segts into 4 layers reflecting the transmural extent of infarction. Late contrast 
enhancement was used to identify infarcted (IM-late enhancement), viable (VM-regional 
dysfunction with no enhancement), and normal myocardium (NM). LV systolic global wall 
stress (WS) was calculated from LVESV, LV mass (both indexed by division with body 
surface area) and systolic BP. 
Results: Thestrongest correlation of BNP was with total dysfunctional myocardium (ie 
numbers of segts with abnormal function). This was superior to correlations with infarcted 
and viable myocardium, and clearly superior to correlations with LVESV, LVEF and WS 
(Table). There was no meaningful correlation with a range of clinical factors. In a multi- 
variate model, the only independent predictor of BNP was total dysfunctional myocar- 
dium (beta 0.63, pcO.0001) 
Correlation Between Log BNP and Other Parameters 
Total Dysfunctional IM VM NM LVES LVEF WS 
Myocardium V 
r 0.640 0.580 0.561 -0.640 0.406 0.419 0.397 
p <0.0001 <o.ooo 0.001 co.000 0.001 0.001 0.066 
1 1 
Conclusion: In patients with ischemic LV dysfunction, the amount of dysfunctional myo- 
cardium (rather than its nature) is an important determinant of BNP more so than LVEF 
or even ws. 
1013-78 Can the Presence of an S3 Predict Elevated B-Type 
Natriuretic Peptide Levels? 
Greaorv M. Marcus Andrew D. Michaels, Teresa A. DeMarco, Kanu Chatterjee. 
University of California, San Francisco, San Francisco, CA 
Background: B-type natriuretic peptide (BNP) has been shown to be a sensitive and 
specific marker of congestive heart failure (CHF). Levels of this hormone demonstrate 
accurate correlation with left ventricular end-diastolic pressure and predict prognosis in 
heart failure patients. The presence of a third heart sound in older adults is thought to 
reflect left ventricular volume overload, with recent data demonstrating an adverse prog- 
nosis in CHF patients with this physical finding. An association between BNP levels and 
the presence of an 53 has not previously been studfed. We hypothesized that ausculta- 
tion of an S3 in older patients reflects elevated BNP levels. 
Methods: BNP levels (Biosite, San Diego, CA) ware measured in 75 consecutive 
patients visiting a general cardiology outpatient clinic. On the day that BNP was mea- 
sured, a single experienced cardiologist (K.C.) blinded to BNP levels auscultated each 
patient in the supine and left lateral decubitus positions. The patients’ primary diagnoses 
were determined by chart review, and the presence or absence of overt CHF was deter- 
mined clinically on the day of the examination. 
Results: 77% of the patients were male, 55% had coronary artery disease, and 11% had 
dilated cardfomyopathy. The mean age was 73*13 years and the mean BNP level was 
263i257 pglml. 26% of patients were diagnosed with overt CHF, and 23% ware found to 
have an S3. The mean BNP level of those with oven CHF was 502 pglml, and the mean 
BNP level of those without overt CHF was 165 pg/ml (p=O.O00006). The mean BNP level 
of those with an S3 was 505 pg/ml, and the mean BNP level of those without an S3 was 
192 pgiml (p=O.O0007). All patients with an 53 had overt CHF. A BNP level > 100 pg/ml 
was 100% sensitive and 50% specific for the presence of overt CHF. The prasence of an 
53 was 46% sensitive and 100% specific for a BNP level > 100 pgiml. 
Conclusiorr In an elderly patient population with cardiovascular disease, the presence 
of an S3 is 100% specific for BNP levels > 100 pglml. 
1013-79 Bedside B-Type Natriuretic Peptide in the Emergency 
Diagnosis of Systolic and Nonsystolic Heart Failure: 
Results From the Breathing Not Properly (BNP) 
Multinational Study 
Alan S. Maisel Radmila Kazanegra, Peter A. McCullough, James McCord, Richard M. 
Nowak, Judd E. Hollander, Alan H. Wu, Philippe Due, Torbjorn Omland, Alan B. Storrow, 
Padma Krfshnaswamy, William T. Abraham, Paul Clopton, Philippe Gabriel Steg, Arne 
Westheim, Cathrine Wold Knudsen, Howard C. Herrmann, Veterans Administration 
Healthcare System, San Diego, CA, University of Missouri-Kansas City School of 
Medicine, Truman Medical Center, Kansas City, MO 
Background Preserved systolic function is increasing common in patients presenting 
with symptoms of congestive heart failure (CHF), but is still difficult to diagnose. This 
study examines B-type natriuretic peptide (BNP) levels in patients with systolic versus 
non-systolic dysfunction presenting with shortness of breath. Methods: The BNP Multi- 
national Study was a seven center, prospective study of 1566 patients who presented 
with acute dyspnea and had BNP measured upon arrival.. A subset of 452 patients with a 
final adjudicated diagnosis of congestive heart failure who underwent echocardiography 
within thirty days of their visit to the emergency department ware evaluated. An ejection 
fraction of greater than 45% was defined as non-systolic CHF. Results: Of the 452 
patients with a final diagnosis of congestive head failure, 165 (36.5%) had preserved left 
ventricular function on echocardiography while 207 (63.5%) had systolic dysfunction. 
Patients with non-systolic heart failure (NS-CHF) had significantly lower BNP levels than 
those with systolic heart failure (SCHF)(413 pg/ml versus 621 pg/ml p <O.OOl). As the 
severity of head failure worsened by NYHA, the percentage of S-CHF increased whrle 
the percentage of NS-CHF decreased. When patients NS-CHF were compared to 
patients without CHF (n=770). a BNP value of 100 pg/ml had a sensitivrty of 86%, a neg- 
ative predictive value of 96%, and an accuracy of 75% for detecting abnormal diastolic 
dysfunction. Using Logistic regression to differentiate S-CHF from NS-CHF. BNP entered 
first as the strongest predictor followed by oxygen saturation, history of myocardial infarc- 
tion, and heart rate.Conclusions We conclude that NS-CHF is common in the setting of 
the emergency department and that differentiating NS-CHF from S-CHF IS difficult in this 
setting using traditional parameters. While BNP levels add modest discrimmatory value 
rn differentiating NS-CHF from S-CHF, its major role is still the separation of patients with 
CHF from those without CHF. 
1013-80 N-T Pro-BNP and the Diagnosis of Heart Failure: A 
Pooled Analysis of Three European Epidemiological 
Studies 
Theresa A. McDonaah, llan Raymond, Stephan Holmer. Andreas Luchner, Per 
Hildebrandt, Henry J. Dargie, University of Glasgow, Glasgow, Umted Kingdom 
BackgroundMany studies have reported the efficacy of BNP in dragnosing heart failure 
(HF) using the optimum concentration on ROC analysis as their cut-point However, in 
routine clinical practice a cut-point reflecting abnormality has to be applied. This study 
reports the use of NT-pro_BNP (proBNP) in detecting HF in a metanalysis of three epide- 
mrological studies. 
Methods: 3052 subjects were pooled from three European Population-Based studies of 
LV Dysfunction, which had collected compatible clinical information and measured 
plasma proBNP (MTP assay Roche) In particular 549 subjects were normal i.e.free of 
cardiovascular disease. As proBNP concentrations mse with age and were higher in 
women ,an abnormal proBNP was defined as >95th centile.corrected for age and sex. HF 
was defined as a LVEF by echo cardiography 4.5the centile for the normal range of 
each centre and symptoms of dyspnoea and/or loop diuretrc therapy. 
Results: The prevalences of HF and LVD were 3.1% and 10% The median concentra- 
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tions of proBNP (pg/ml) in those with HF and LVD were 269 and 117, respectively and 
were significantly higher than normals (20pg/ml), p<O.OOl. The AUC on ROC analysis for 
the diagnosis of HF in the cohort was 0.85. In a multiple logistic regression analysis the 
independent predictors of HF (Odds Ratios) were IHD (3.9), a log unit increase in 
proBNP (2X), diabetes (2.2), hypertension (2) and increasing age (1.4). Our cut-point for 
“an abnormal proBNP” rssjlted in a sensitivity of 75%, specificity of 79% and a negative 
predictive value of 99% for detecting HF. In this population an abnormal pro-BNP value 
was explained by a significant cardiac structural, functional or renal problem in 89% of 
cases. Restricting our analysis to subjects with dyspnoea, we could explain 95% of high 
proBNP values on the basis of cardiac or renal dysfunctron. We had 22 ‘false negative” 
dyspnoeic subjects. Of these 16 (72%) were on cardiovascular medication which could 
reduce proBNP levels. 
Conclusions:This large pooled population analysis conflrms the usefulness of pro-BNP 
in diagnosing heart failure and has demonstrated what “hyperBNPaemia” is due to when 
cut-points based on abnormality are applied. 
1013-81 Tailoring Beta-Blocker Therapy in Patients With Chronic 
Heart Failure Utilizing NT-Pro-BNP 
Nicola Johnston, Mary Green, Stephen Robb, Ian Morton, Henry Dargie, Western 
Infirmary, Glasgow, United Kingdom 
Studies have provided evidence that beta-blockers (BE) decrease mortality in patients 
with chronic heart failure (CHF). However, surveys carried indicate the use of BB in clini- 
cal practice is still low (between 9% and 52%). This is partly due to difficulties III imple- 
mentation of BB and reluctance to commence BB in the community. The aim of this study 
was to examine implementation of BB in a heart failure clinic and to assess the use of 
NT-pro BNP to predict toleration of BB therapy. 
115 consecutive patients referred to the CHF clinrc for commencement of BB were 
included. Data collected detailed aetiology of CHF, co-morbidity and concurrent drug 
therapy, as well as LV function from the initial echocardiogram. At visit 1 the lowest 
licensed dose of 88 was started and doubled every 2 weeks until maximum dose was 
achieved. Patients were observed for 2 hours each visit, and pulse and blood pressure 
were recorded every 30 minutes. Physical examination was carried out at each atten- 
dance assessing weight, JVP, peripheral oedema and chest signs of pulmonary oedema. 
Side-effect profile was recorded, as well as follow-up data on drug compliance. NT-pro 
BNP was measured at initial visit and on average every 3 months thereafter. Average 
age was 67 (range 19-88 years of age). Of the patients referred 48.7% had severe LVD. 
45.0% moderate LVD and 6.3% mild LVD. 89.5% patients tolerated BB therapy with 
41.9% established on full dose therapy. Average time taken to establish the patient on 
their maximum tolerated dose was 10 weeks (range 8-44 weeks). Multivariate analysis 
was performed using Cox regression analysis. The only significant, independent, predic- 
tors of toleration of BB therapy were NT-pro BNP level before commencement of BB and 
during uptitration of BB. The higher the NT-pro BNP level, the less likely the patient was 
to tolerate BB therapy. A history of COPD or PVD did not predict toleration of BB and nor 
did NYHA class or severe LVD. 
BB therapy can be effectively commenced in the majority of patients with CHF. NT-pro 
BNP predicts which patients will tolerate BB therapy and could be of use to determine 
which patients could safely be commenced and uptitrated on BB in the community rather 
than attending hospital supervised programroes. 
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1014-59 B-Type Natriuretic Peptide Levels in Patients With 
Hypertrophic Obstructive Cardiomyopathy Treated With 
Alcohol Septal Ablation 
SteDhen M. Tans Christopher Nielsen, Donna Killip, David S. Feldman, William H 
Spencer, Ill, Medical University of South Carolina, Charleston, SC 
Background: In patients with cardiomyopathy, the serum B-type natiuretic peptide 
(BNP) level has been used as a biochemical marker for assessing the degree of heart 
failure decompensation. and as a long-term prognostic indicator. BNP has been shown 
to be elevated in both systolic and diastokc heart failure. Patients with hypertrophic 
obstructive cardiomyopathy (HOCM) exhibit symptoms of decompensated heart failure 
based on left ventricular outflow tract (LVOT) obstruction and diastolic dysfunction. The 
purposes of this study were to determine if BNP levels are elevated in patients with 
symptomatic HOCM, and if these levels would decrease with successful alcohol septal 
ablation. Methods: Serum BNP levels were drawn in 10 consecutive patients at base- 
line, 24 and 48 hours. Peak LVOT gradients at rest and with Valsalva were measured by 
echo Doppler pre and post procedure. Results: See table below: 
Pre-Ablation 24 hours post ablation 48 hours post ablation 
BNP (peg/ml) 578 +I- 155 193 +I- 55 172 +/- 22 
LVOT rest (mmHg) 70.6 +I- 7.4 14.8 +I- 1.8 
LVOT valsalva (mmHg) 104.3 +/- 8.4 40 +/- 5.7 
After alcohol septal ablation, serum BNP levels decreased by 67% at 24 hours 
(p=O.O24), and 71% at 48 hours (p=O.O14). The resting LVOT gradient decreased by 
79% (p<O.OOOl) after the procedure, and with Valsalva the LVOT gradient decreased by 
62% (p<O.OOOl). Conclusions Serum BNP levels are elevated in patients with elevated 
peak LVOT gradients and symptomatic HOCM. Successful treatment with alcohol septal 
ablation produced a marked decrease in peak LVOT gradient and serum BNP levels. 
BNP levels may be considered as a surrogate marker for therapeutic success after alco- 
hol septal ablation. 
1014-60 Echo-Guided Septal Ablation for Hypertrophic 
Obstructive Cardiomyopathy: Six.Years of Experience 
Lothar Faber, Dirk Welge, Hubert Seggewiss, Dieter Fassbender, Ulrich Glerchmann. 
Dieter Horstkotte, Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany, 
Leopoldma Hospital, Schweinfurt. Germany 
Background: Ethanol-induced septal ablation for symptomatic hypertrophic obstructive 
cardiomyopathy (HOCM) requires the exact definition of the septal myocardium to be 
abladed. We report on our cumulative experience with PTSMA guided by intra-proce- 
dual contrast echo (MCE) on an intention-to-treat basis in 322 patients (pts.) treated 
from 1 /1996 - 12/2001. 
Aesuks: Ethanol could not be infected I” 26 pts. (8%), predominantly due to an 
unwanted extension of the target region as documented by MCE in 18 pts. (6%). In 33 
out of the 296 pts. pts. (11%) who received ethanol, a target vessel (TV) change was 
necessary for the same reason. In-hospital mortality was 1.4% (4 pts.). After 3 months, 
symptoms had improved in 262 pts. (69%) from NYHA class 2.8r0.5 to 1.520.6, with a 
mean increase in exercise capacity by 21+46 watts (p<O.OOOl each). 157 pts. (53%) 
reported to be free of symptoms. A satisfactory mid-term (3 months) reduction of the left 
ventricular outflow gradient (LVOTG) was achieved in 243 pts. (82%; from 56+33 to 
13+18 Hg at rest and 119*44 to 37-35 mm Hg with provocation; pcO.0001). 119 pts. 
(43%) were free from outflow obstruction. LVOTG with probatory balloon occlusion dur- 
ing the intervention was 39+31 mm Hg (p<O.OOi). There was a weak correlation between 
the LVOTG with probatory balloon occlusion (PBO) and the residual LVOTG after 3 
months (0.3; pcO.001). PBO-induced LVOTG reduction was >30% in 159 pts. (54%) and 
>50% in only 112 pts. (38%). 
Conclusions: In case of a positive intra-procedural MCE study, PBO adds llttle informa- 
tion with respect to lV selection in PTSMA for HOCM. Furthermore, MCE is able to 
exclude alcohol necrotization of myocardium remote from the septal target area, and 
thus adds to the safety of the procedure. 
1014-61 Insulin-Like Growth Factor-l Attenuates Myocardial 
Hypertrophic Response to Sarcomeric Mutations in 
Human Familial Hypertrophic Cardiomyopathy 
David A. Bealey, Said1 A. Mohiddin. Andrew E. Arai, Jing-Ping Lin, Dorothy Tripodi, 
Lameh Fananapazir, National Institutes of Health, Bethesda, MD 
Background: Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in sar- 
comeric contractile proteins. Impaired sarcomeric function leads to expression of a vari- 
ety of genes, resulting in compensatory left ventricular (LV) hypertrophy. The severity of 
the cardiac hypertrophy is an important determinant of clinical outcome. LV hypertrophy, 
is however, highly variable in affected family members with an idendical disease muta- 
tion. The reasons for the marked differences in phenotypic expressron are not known. 
Insulin-like growth factor-l (IGF-1) plays an important role in cardiomyocyte viability and 
function. We therefore hypothesized that variations in IGF-1 levels account for some of 
the phenotypic heterogeneity in FHC. Methods: Plasma IGF-1 and its binding protein 
IGFBPS, and LV indices measured by magnetic resonance imaging, were measured in 
100 subjects with diverse mutations causal for FHC (mean age, 30+2 years; 43 males), 
and 50 normal family members without disease mutation (controls). Results: IGF-1 levels 
increased between the ages of 5 and 20 years and decreased thereafter. IGF-1 levels 
were lower in FHC subjects but the decline with age in adults was similar to controls. In 
subjects with sarcomeric gene mutations, maximum LV wall thickness (LVWT) varied 
between 9 mm to 44 mm and correlated poorly with LV mass. There was a significant 
inverse correlation between IGF-1 levels (but not IGFBPB) and maximum LVWT in this 
subset (p=O.OOS), when age, gender, body surface area, IGFBP-3. and relation among 
family members in the study were controlled for. Notably, IGF-1 levels also correlated 
significantly with maximum LVWT:LV diastolic volume (p=O.O0026), a ratio which reflects 
LV wall stress. 
Conclusions: Elevated IGF-1 levels are protective and are associated with milder FHC 
phenotype, possibly because the increased IGF-I activity lessens myocyte contractile 
dysfunction induced by sarcomeric mutation, thereby attenuating the myocardial hyper- 
trophlc response. Our findings indicate that the use of octreotide to reduce IGF-1 levels 
in HCM, suggested by some workers, may have deleterious effects 
